Biomoda Appoints Three Business Leaders to Board of Directors

New members will help commercialize innovative technologies for early lung cancer detection

Biomoda, Inc. a development stage medical diagnostics company, today announced the election of three business leaders, Maria Zannes, David Lambros, and Lewis White, to its Board of Directors. The Board Members’ terms as Directors begin May 1.

U.S. Patent and Trademark Office Grants Biomoda Notice of Allowance for Patent Protection for Additional Intellectual Property

Allowance allows company to expand patent portfolio of technologies for early detection of lung cancer

Albuquerque, N.M., April 16, 2008 –Biomoda, Inc. (OTC Bulletin Board: BMOD) (www.biomoda.com), a development stage medical diagnostics company, announced it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its invention directed to the “Method for Prognosing Response to Cancer Therapy with 5,10,15,20-Tetrakis (Carboxyphenyl) Porphine.”

Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting

Company seeks to collaborate on latest research technologies

Albuquerque, N.M., April 10, 2008 – Researchers and executives from Biomoda, Inc. (OTC Bulletin Board: BMOD) (www.biomoda.com), a development stage medical diagnostics company, will present a paper entitled, “New Non-Invasive Technology for the Early Detection of Cancer at the Cellular Level” at the 83rd Annual Multidisciplinary Meeting of the American Association for the Advancement of Science (AAAS) Southwestern and Rocky Mountain (SWARM) Division, Thursday, April 10, at the University of New Mexico in Albuquerque.

Tobacco money propels Biomoda lung cancer technology

The New Mexico Legislature included $1.3 million in its fiscal year 2009 budget proposal to study new technology for rapid detection of lung and other cancers.

The technology is being developed by Albuquerque's Biomoda Inc. based on discoveries made at Los Alamos National Laboratory 20 years ago. Biomoda licensed the technology in the early 1990s and has worked more than 15 years to develop it into a marketable product for clinical diagnostics and possibly new cancer therapies.

New Technology for Early Detection of Lung Cancer Selected for Clinical Study with Veterans

Albuquerque, N.M., February 14, 2008 – The New Mexico Institute of Mining and Technology (New Mexico Tech) and Biomoda, Inc. (OTC Bulletin Board: BMOD) (www.biomoda.com), have partnered with the New Mexico Department of Veterans Services (DVS) to conduct a $350,000 clinical study using proprietary testing technology for detection of early lung cancer in the state’s veterans.

Biomoda and Medical Acoustics Partner in Study for Early Detection of Lung Cancer in Veterans

Albuquerque, N.M., February 13, 2008 – Biomoda, Inc. (OTC Bulletin Board: BMOD), a maker of patented early lung cancer detection testing and other cancer diagnostic technology, today announced a collaborative agreement with Medical Acoustics, LLC, to collect lung sputum samples in an upcoming clinical study that will use Biomoda’s proprietary testing technology for detection of early lung cancer.

NEW MEXICO VETERANS CONVERGE ON STATE CAPITOL FOR “VETERANS VISITING THEIR GOVERNMENT DAY”

SANTA FE, N.M., January 28, 2008 – Busloads of New Mexico veterans representing thirteen veterans’ organizations will meet legislators January 29th as part of “Veterans Visiting Their Government Day” at the Capital. Hundreds of veterans and their families representing the Veterans of Foreign Wars (VFW), American Legion, Am-Vets, Disabled American Veterans, Black Veterans Association of New Mexico, Veterans’ Council, Women Veterans of New Mexico, Buffalo Soldier Association, Military Order of the Purple Heart, Paralyzed Veterans of America, Jewish War Veterans, Korean War Veterans, and VS Volunteers will board buses in Taos, Espanola and Albuquerque as the sun rises to take part in the day’s ceremonies, including meetings in support of their legislative agenda at the Round House.

Biomoda Strengthens Lobbying Efforts

ALBUQUERQUE, N.M., January 22, 2008/PRNewswire-FirstCall/-- Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology announced today it has retained the services of Terry McDermott of McDermott Consulting to facilitate communication and lobbying efforts during the current 2008 New Mexico Legislative session.

NEW MEXICO VETERANS CALL FOR STATE FUNDING OF EARLY LUNG CANCER SCREENING USING BIOMODA TECHNOLOGY AT “VETERANS’ DAY”

SANTE FE, N.M., January 21, 2008/PRNewswire-FirstCall/-- Busloads of New Mexico veterans will meet state legislators January 29th as part of “Veterans Day” in Santa Fe to push for $1.3 million in funding of an early lung cancer screening program for veterans being conducted by New Mexico Tech University and Biomoda (OTC Bulletin Board: BMOD) (http://www.biomoda.com), an Albuquerque biomedical company that has developed a non-invasion test for early detection of lung cancer .

Biomoda Hires Senior Scientist to Expand Research & Development Effort

ALBUQUERQUE, N.M., January 11, 2008/PRNewswire-FirstCall/-- Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology announced todayDr. Stephen M. Gomez has joined Biomoda as a Senior Research Specialist focused on the company’s efforts to commercialize its assay for the early detection of lung cancer.

Biomoda Announces Collaborative Agreement with New Mexico Tech

ALBUQUERQUE, N.M., December 12, 2007 /PRNewswire-FirstCall/-- Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology, and New Mexico Institute of Mining and Technology (New Mexico Tech at http://www.nmt.edu ) reached an agreement today to collaborate on clinical studies and the development of specialized image recognition technology as part of the company’s commercialization of its assay for the early detection of lung cancer.

Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm. (Addition)

ALBUQUERQUE, N.M., Nov. 28 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD - News; http://www.biomoda.com), maker of early-detection cancer diagnostic tests, has approved MicroCap Management as the front-runner of its full media campaign. MicroCap Management has created a strategic media plan that will provide a launch pad for present and future business driven by the progressive vision of Biomoda's Senior Executive Officers.

Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.

ALBUQUERQUE, N.M., November 26, 2007 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), maker of early-detection cancer diagnostic tests, has approved MicroCap Management as the front-runner of its full media campaign. MicroCap Management has created a strategic media plan that will provide a launch pad for present and future business driven by the progressive vision of Biomoda’s Senior Executive Officers.

Biomoda Hires Senior Scientist to Head Research & Development Effort

ALBUQUERQUE, N.M., November 19, 2007 -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today Dr. Leo Gomez has joined Biomoda as Director of Research, spearheading the company’s research efforts towards commercialization of its assay for the early detection of lung cancer.

Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts

Albuquerque, N.M., October 31, 2007 -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today it hired Manzano Strategies LLC, a government consulting firm focused on building government partnerships with companies interested in defense appropriations and development of advanced technologies.

Biomoda and Clinical Research Center of Cape Cod Reach Agreement for Clinical Services

Albuquerque, N.M., October 25, 2007 -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today an agreement with Clinical Research Center of Cape Cod (CRCCC) of West Yarmouth, Mass. to provide lung sputum samples for Biomoda’s internal clinical programs.

Two Scientists Join Team of Biomoda, Inc.

Albuquerque, NM October 15, 2007 -- Two clinical research scientists this month joined Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, to assist with commercialization efforts of the company’s early lung cancer detection testing and other cancer diagnostic technology.

Biomoda, and Averion International Announce Agreement for Clinical Services

Albuquerque, NM October 4, 2007 -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today an agreement with Averion International Corporation of Southborough, Mass. to provide a range of clinical services
including protocol design and study implementation for Biomoda’s clinical programs.

. . . read the release

Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer.

Santa Fe, NM October 2, 2007 -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, testified Monday before the New Mexico State Legislature’s Interim Tobacco Settlement Committee in support of the lawmakers’ $1.3 million proposal for funding a clinical study using the company’s assay for early lung cancer detection.

WallSt.net Announces Upcoming Interview with CEO of Biomoda

New York—John Cousins, Chief Executive Officer of Biomoda, Inc. (OTCBB: BMOD) (http://www.biomoda.com) will be featured in an exclusive interview with www.wallst.net scheduled for September 28 at 1 p.m. EDT. The interview will be posted on www.wallst.net by 8 p.m. EDT on September 28.

Biomoda, Inc. and TriCore Reference Laboratories Announce Collaboration on Clinical Research Studies

Albuquerque, NM September 17, 2007 -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today TriCore Reference Laboratories of Albuquerque will conduct assay preparation, testing and analysis of Biomoda’s proprietary test for detection of early lung cancer as part of the company’s clinical programs

Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting

Albuquerque, NM September 10, 2007 -- Biomoda, Inc.(OTC Bulletin Board :BMOD) (http://www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today an agreement with Quintiles Consulting of Rockville, Md., for regulatory consulting and design of clinical studies of Biomoda’s proprietary test for detection of early lung cancer as part of the company’s clinical programs.

. . . read the release

Biomoda Files Patent Protection to Speed Up Marketing of its Lung Cancer Detection Technology

Biomoda, Inc., Albuquerque, NM www.biomoda.com, Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology, disclosed today that it is again expanding its intellectual property portfolio with an additional unique patent pending to enhance the stability and greatly increase the shelf-life of its assay. This potentially extraordinary step is looked to both save large sums in testing and expedite bringing to market of Biomoda’s patented porphyrin molecule to detect different cell variations of lung cancer.

Biomoda Files Additional Patent Protection for its Lung Cancer Detection Technology

Biomoda, Inc., Albuquerque, NM www.biomoda.com, Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology, confirmed today that it is continuing to expand its patent portfolio with a unique patent pending for the use of its patented porphyrin molecule to detect different cell variations of lung cancer.

Biomoda Files for Patent Protection for its Cancer Imaging and Therapy Molecule

Biomoda, Inc. (OTC Bulletin Board: BMOD), Albuquerque, New Mexico, (www.biomoda.com), maker of patented early lung cancer detection testing and other cancer diagnostic technology, said today that it is expanding its patent portfolio with an additional patent pending for the use of its patented porphyrin molecule as part of a sophisticated cancer drug delivery system. 

. . . read the release

Biomoda Featured At Crossroads of the World, Times Square in New York City

Biomoda, Inc., Albuquerque, NM www.biomoda.com, Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology, will be featured today in New York City’s Times Square on the Reuters Sign, which soars 23 stories into the sky and is seen by more than 1.5 million people daily.

Biomoda Appoints Former Los Alamos Senior Scientist to Board of Directors

Biomoda, Inc. (OTC Bulletin Board: BMOD), Albuquerque, New Mexico, (www.biomoda.com), maker of patented early lung cancer detection testing and other cancer diagnostic technology, said today that Albert Goodman, Ph.D., a former Senior Scientist who has been involved in key experimentation at Los Alamos National Laboratories and Sandia National Laboratories, has been elected to its Board of Directors. 

. . . read the release

Biomoda, Inc. Retains E & E Communications to Assist with Investor and Public Relations

Biomoda, Inc., Albuquerque, NM www.biomoda.com, Biomoda, Inc. (OTC Bulletin Board: BMOD - News), Albuquerque, New Mexico, (http://www.biomoda.com) , maker of patented early lung cancer detection testing and other cancer diagnostic technology, today announced that it has retained E & E Communications, Laguna Hills, California, to assist with its investor and public relations efforts.

Biomoda, Inc. Now Represented by Fortune 500 Firms’ Marketer

Biomoda, Inc., Albuquerque, NM www.biomoda.com, maker of patented early lung cancer detection testing and other cancer diagnostic technology, has been accepted for representation by Synergistic Marketing www.4synergistic.com, which among other clients has represented Fujitsu FCPA-Medical MO Ultrasound Recording; Bell and Howell-Kodak Service; American Airlines-Wireless Logistics; and five Hitachi Units, including Medical Records Tech and MRI Imaging. 

. . . read the release

Biomoda, Inc. Approved by Standard & Poor’s for Publication

Biomoda, Inc., Albuquerque, NM www.biomoda.com, maker of patented early lung cancer detection testing and other cancer diagnostic technology, just received notification that it was approved by Standard & Poor’s to be carried in S&P’s Daily News and S&P’s Corporation Records.

Biomoda Technology Could Help Resolve Issues Over Lung Cancer Early Screening

A recent study published in the Journal of the American Medical Association questions the efficacy of CT scans for the early detection of lung cancer and its relationship to improved mortality rates. This is further evidence that the first-step, non-invasive screening test developed by Biomoda will be an essential tool for more accurate detection and treatment of lung cancer, said John Cousins, President of Biomoda, Inc. (www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology. Biomoda, Inc. trades on NASDAQ's OTC Bulletin Board under the ticker symbol "BMOD".

. . . read the release

Biomoda, Inc. Moves to License Its Patented Technology in Russia, Eastern Europe and Asia

Biomoda, Inc. of Albuquerque, NM, (OTC Bulletin Board: BMOD, www.Biomoda.com) maker of early lung cancer detection testing and other cancer diagnostic technology, disclosed ongoing negotiations with San Francisco based Cureline, Inc., www.CurelinePartners.com, a multi-national biomedical sample management company, to license Biomoda’s Patented diagnostic technology for sale in Russia, Eastern Europe and Asia.

Biomoda, Inc. CEO Featured in Exclusive Interview with WallSt.net

John Cousins, Chairman, President and CEO of Biomoda, Inc. (OTC Bulletin Board: BMOD, www.biomoda.com) updated the investment community in an all-new interview with www.wallst.net . Biomoda is developing early lung cancer detection testing and other cancer diagnostic technology and tools. Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, and upcoming strategic and financial milestones.

. . . read the release

Transcript Interview with WallStreet.net

. . . read the release

The conclusions of a new study that second-hand smoke doubles the risk of lung cancer offers greater evidence of the need for widespread use of early lung cancer screening, said John Cousins, President of Biomoda, Inc. (“BMOD”) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology.

. . . read the release

A recent report by the American Cancer Society is strong evidence in support of widespread use of early lung cancer diagnostic testing to save lives, according to John Cousins, President of Biomoda, Inc. (www.biomoda.com) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology. Biomoda, Inc. trades on NASDAQ’s OTC Bulletin Board under the ticker symbol “BMOD”.

. . . read the release

Biomoda, Inc. (OTCBB: BMOD) of Albuquerque, NM, (www.biomoda.com) maker of early lung cancer detection testing and other cancer diagnostic technology, announced it’s membership in BIOCOM, (www.biocom.org) a premiere life science industry association that focuses on capital formation, public policy, workforce development, and scientific discovery and development.

. . . read the release

Biomoda, Inc. of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced its agreement with Northport Associates to direct Biomoda’s government and public affairs efforts. Northport will spearhead Biomoda’s state and federal lobbying to secure funding for its programs to screen military personnel and veterans for lung cancer using Biomoda’s proprietary assay. Biomoda trades on NASDAQ's OTC Bulletin Board: ticker symbol “BMOD”.

. . . read the release

Biomoda, Inc. (OTCBB: BMOD) of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today that it signed an agreement with Cureline, Inc., a multi-national medical sample acquisition company, www.cureline.com to collect and provide sputum samples for Biomoda's ongoing validation and development work.

. . . read the release

Biomoda, Inc. (OTCBB: BMOD) of Albuquerque, NM, developer of early lung cancer detection testing and other cancer diagnostic technology, announced today that it has signed an agreement to exclusively license cancer detection technology from Los Alamos National Laboratory.

. . . read the release

Biomoda, Inc. of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced today that its common stock has begun trading on the OTC Bulletin Board under the ticker symbol “BMOD”.

. . . read the release

. . . read the release

. . . read the release

. . . read the release

. . . read the release

. . . read the release

. . . read the release

. . . read the release

. . . read the release

. . . read the release